Skip to main content
Download PDF

Sedative effect of remimazolam combined with alfentanil in colonoscopic polypectomy: a prospective, randomized, controlled clinical trial

BMC Anesthesiology volume 22, Article number: 262 (2022) Cite this article

Abstract

Background

Remimazolam is a newer benzodiazepine with properties of rapid onset, short duration of action, and fast recovery. Our study was to evaluate the effects of different doses of remimazolam combined with alfentanil in colonoscopic polypectomy.

Methods

One hundred twenty patients were randomly divided into four groups: alfentanil and propofol (AP) group, alfentanil and remimazolam 0.1 mg/kg (AR1 group), 0.15 mg/kg (AR2 group), or 0.2 mg/kg (AR3 group). Patients in the four groups received alfentanil 10 μg/kg, followed by propofol 2 mg/kg and three dosages of remimazolam. Modified Observer's Assessment of Alertness and Sedation (MOAA/S) scale, heart rate (HR), oxygen saturation (SpO2), respiratory rate (RR), bispectral index (BIS) values and mean arterial pressure (MAP) were collected at intervals of 5 min and analyzed at different time points: before anesthesia (T0), 5 min (T1), 10 min (T2), 15 min after anesthesia (T3) and at the end of surgery (T4). The average MAP was calculated utilizing the average of all MAP values. The primary outcome was the success rate of sedation. Secondary outcomes included time to full alert and adverse events.

Results

The success rate of sedation was 100% among the four groups. The incidence of hypotension was significantly decreased (all P < 0.05) and the average MAP was higher in AR1-AR3 groups than AP group (all P < 0.001). None of the patients developed bradycardia or hypertension during surgery in all study groups. BIS values were higher (all P < 0.001) and the time to full alert was statistically shorter in AR1-AR3 groups (all P < 0.05) compared with the AP group. The MOAA/S score in AR1 was higher than AR2 (P < 0.05) and the AR3 group (P < 0.05) at T1 and BIS values in the AR1 group were significantly higher than AR3 group (P < 0.05) at T4.

Conclusions

Remimazolam combined with alfentanil have a non-inferior sedative effect than propofol during the colonoscopic polypectomy. Moreover, this combination of two short-acting drugs might be a safer alternative.

Trial registration

The clinical trial was registered on (16/05/2021, ChiCTR2100046492).

Peer Review reports

Background

During colonoscopic polypectomy, a minimally invasive surgical procedure of colonoscopy requires continuous inflation of the abdominal wall to clear the field of vision. Stimulation and traction of the intestinal wall cause excitation of the visceral nerve, resulting in bradycardia, body movement, patient discomfort, and interference with surgery [1]. For procedures like colonoscopic polypectomy requiring minimally invasive surgical interventions, anesthesiologists need to provide adequate sedoanalgesia to provide optimal surgical conditions for 20 to 30 min without respiratory depression desired for the comfort of both the patient and the surgeon, which we call monitored anesthesia care (MAC), in order to prevent complications [2,3,4,5]. However, to keep the airway patent and maintain stable hemodynamics, excessive depth of sedation is also not recommended [5].

Propofol has the advantages of rapid onset and quick recovery and is often used in gastroscopy [6]. However, propofol quickly causes adverse side effects, including hypotension and hypoxemia [7,8,9], and propofol injection pain also cannot be ignored [10]. Alfentanil is a short-acting opioid analgesic with high analgesic intensity and similar complication risks to other opioids. A shorter recovery time makes alfentanil meeting the needs of daytime anesthesia more suitable [11,12,13,14].

Remimazolam is a novel short-acting intravenous benzodiazepine that acts as a positive allosteric modulator of the γ-aminobutyric acid subtype A (GABAA) receptor via the benzodiazepine binding site [15, 16]. It retains the characteristics of benzodiazepines, such as water solubility, antagonism, and no injection pain. It also possesses some pharmacological characteristics of remifentanil due to the methyl propionate side chain in the structure, such as rapid onset, short duration of action, inactivity of metabolites and not being affected by infusion time [17,18,19]. The success rate of sedation of remimazolam was reported to be non-inferior to propofol and provided a lower incidence of adverse events [20, 21]. Nevertheless, there is still no clear conclusion about using alfentanil combined with remimazolam in colonoscopic polypectomy. Therefore, our study aims to evaluate three different dosages of remimazolam combined with alfentanil for sedation induction in patients undergoing colonoscopic polypectomy.

Methods

Study design and setting

This prospective, randomized, controlled pilot trial was designed to observe patients undergoing colonoscopic polypectomy in Tongji Hospital. Tongji Medical College of Huazhong University of Science and Technology Ethics Committee (IORG No: IORG0003571) approved the conduct of the trial. The trial was registered before patient enrollment at http://www.chictr.org.cn (principal investigator: Aijun Xu, date of registration and registration number: 16/05/2021, ChiCTR2100046492) and written informed consent was obtained from all subjects participating in the study. This study follows applicable Consolidated Standards of Reporting Trials (CONSORT) guidelines.

Participants and recruitment

Eligible patients who underwent colonoscopic polypectomy in Tongji Hospital from May 2021 to March 2022 were evaluated according to the inclusion criteria: 1) aged 18 to 80 years; 2) American Society of Anesthesiologists' (ASA) status I or II; 3) operation time is 20 to 60 min; 4) Body Mass Index (BMI) 18.5 to 23.9 kg/m2. The exclusion criteria are as follows: 1) emergency operation; 2) with a high risk of a full stomach and reflux aspiration; 3) allergic to benzodiazepines and opioids; 4) take sedative, analgesic, or antidepressant drugs within 24 h; 5) pregnant or breastfeeding; 6) with abnormal liver and kidney function; 7) with a history of drug abuse; 8) recently participated in other clinical studies; 9) Patients who cannot cooperate with communication. The dropout criteria are as follows: 1) severe adverse events such as massive hemorrhage and intestinal perforation during the operation; 2) participant withdrew informed consent; 3) investigators determined that the patient withdrew if a person had poor compliance, serious complications such as postoperative intestinal perforation in need of emergency surgery and severe infection. Detailed reasons will be recorded, and the case report form (CRF) will be retained for reference.

Randomization and blinding

Randomization was implemented by researchers who were not involved in anesthesia management and intraoperative and postoperative follow-up to avoid selection bias. Patients were randomized into four groups according to the randomized number lists generated by Statistical Package for Social Sciences (SPSS) software version 26.0. Randomized numbers were sealed in numbered opaque envelopes according to which patients were included.

In this study, a single-blind study method was adopted. An investigator was assigned to determine the order of patients and coordinate the relationship between researchers. Another investigator, blinded to the study protocol and trained on evaluation methods before the study, performed the preoperative evaluation and postoperative follow-up. An anesthesiologist performed anesthesia management and intraoperative data collection. The statistical experts of Tongji Hospital analyzed the final data. All researchers except anesthesiologists were blinded to the grouping.

Anesthesia management and intervention

Patients who underwent bowel preparation were established venous access and introduced 250 mL 0.9% sodium chloride solution when brought to the endoscopy room. Blood pressure (BP), heart rate (HR), oxygen saturation (SpO2), respiratory rate (RR) and bispectral index (BIS) were routinely monitored. Following lateral positioning, an oxygen inhalation mask was administered immediately at a rate of 3L/min. The patients in the alfentanil and propofol (AP) group were administered alfentanil (Yichang Humanwell Pharmaceutical, Co., Ltd., China, 13S03051) 10 μg/kg and propofol (Corden Pharma S.P.A., RX061) 2 mg/kg [22,23,24,25]. Patients in remimazolam groups were received alfentanil 10 μg/kg, followed by remimazolam besylate (Yichang Humanwell Pharmaceutical, Co., Ltd., China, 70,705,021) 0.1 mg/kg (AR1 group), 0.15 mg/kg (AR2 group), or 0.2 mg/kg (AR3 group). It took over 1 min to induce sedation for all patients. When the Modified Observers Assessment of Alertness and Sedation (MOAA/S) score ≤ 1 [24], colonoscopy was performed by the same endoscopist who had over ten years of experience. Remimazolam was administered strictly following the instruction, as shown in Fig. 1. Additional 1/3 to 1/2 of the initial dose of alfentanil or propofol and 2.5 mg remimazolam were administered to keep the appropriate sedation and painless according to the surgery duration. If the initial and supplemental boluses of remimazolam reached the maximum dose according to instruction within a 15-min window, 0.5-1 mg/kg propofol was administered as rescue sedative medication when requested to maintain enough sedation (MOAA/S score ≤ 1). Artificial assisted ventilation was given immediately if a decrease in SpO2 to less than 90% and sustained for more than 20 s, which was regarded as respiratory depression associated with sedation [26]. If obvious hypotension (20% lower than base value) and bradycardia (HR is less than 60 beats per minute) occur, ephedrine and atropine were given to maintain circulation stability.

Fig. 1
figure 1

The administration of remimazolam at sedation induction

Full size image

Postoperative management

After surgery, patients were monitored in the post anesthesia care unit (PACU). After meeting the PACU standards (Steward score > 4), patients were transferred to the ward. Follow-up was performed to evaluate postoperative adverse reactions 24 h after the surgery, including hypotension, hypertension, bradycardia, tachycardia, pain, vertigo, nausea, vomiting, and intraoperative awareness.

Outcomes and data collection

Baseline demographics and case characteristics were recorded, such as age, sex, height, and weight. The primary outcome is the success rate of sedation. Successful sedation for the colonoscopic polypectomy was defined based on a previous study [21] as follows: (1) completion of the procedure, (2) no requirement for a rescue sedative, (3) administration up to a maximum of five supplemental doses within 15 min of the initial dose.

The secondary outcomes were (I) time of anesthesia; (II) time of operation; (III) time to full alert; (IV) duration of PACU; (V) dose of drugs used for anesthesia management; (VI) intraoperative adverse reactions such as body movement, cough, hypotension, hypertension, bradycardia, tachycardia, (VII) postoperative adverse reactions including hypotension, hypertension, bradycardia, tachycardia, pain, vertigo, nausea, vomiting, intraoperative awareness.

MOAA/S scale (Table 1) was recorded to determine the level of sedation every five minutes from anesthetic administration until the end of the procedure. MAP, HR, SpO2, BIS and RR were recorded every five minutes. The average MAP was calculated utilizing the average of all MAP values collected at intervals of 5 min during the operation [27].

Table 1 Modified Observer's Assessment of Alertness and Sedation (MOAA/S) Scale
Full size table

Sample size

Prior studies suggested the success rate of sedation was 96.52% to 97.34% for remimazolam and 100% for propofol applied in colonoscopy [20, 21, 28]. In our trial, propofol combined with alfentanil served as an active control. A non-inferiority test was put into effect on the four groups' primary outcome (the success rate of sedation). The predefined non-inferiority margin was 8%. The sample size was calculated using Power Analysis and Sample Size (PASS) 15.0.5 software based on the following parameters: the success rate of sedation was 96.93% (the median of 96.52% to 97.34%) of remimazolam and 99.99% of propofol, the ratio of remimazolam groups (0.1 mg/kg, 0.15 mg/kg and 0.2 mg/kg) to propofol group was 3:1. A sample size of 26 per group was calculated using two-sided type I error rate of 5% (α = 0.05) and 80% power (β = 0.1). We estimated that 15% dropped out of the study; thus, 30 cases for each group had to be included. Finally, 120 patients were included as the sample size in this study.

Statistical analysis

The Shapiro–Wilk test was used to determine the normal distribution of continuous variables. According to the distribution, the mean ± standard deviation (SD) or median (interquartile range) were used to describe continuous variables. Numbers (percentage) were used to describe categorical data (such as gender and MOAA/S scores). Continuous variables were analyzed using one-way analysis of variance (ANOVA) or Welch ANOVA based on the homogeneity of variance test and Kruskal-Walli's test and then followed by Bonferroni's post hoc test or Games-Howell's post hoc test to compare differences among groups. Categorical variables were compared using Pearson's chi-square test or Fisher's exact test, followed by Bonferroni's post hoc test. P value < 0.05 was considered statistically significant. Date analyses were generated by SPSS software version 26.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA).

Results

One hundred thirty-one patients were assessed for eligibility and 11 were excluded because of age, BMI and severe existing physical illnesses such as renal failure, heart failure, and cerebral infarction. 120 patients were randomized into four groups (n = 30 for each group). Protocol deviations included the withdrawal of informed consent (n = 6, Fig. 2). The baseline demographic of all groups was presented in Table 2.

Fig. 2
figure 2

CONSORT flow diagram of participants

Full size image
Table 2 Patient demographics
Full size table

Primary outcome

The success rate of sedation during the colonoscopic polypectomy was 100% among the four groups (Table 3).

Table 3 The success rate of sedation
Full size table

Secondary outcomes

The secondary outcomes among the four groups were summarized in Table 4. There were no meaningful differences in the time of anesthesia (P = 0.794) and operation (P = 0.823) among all the groups. The time to full alert and PACU duration were significantly shorter in AR1—AR3 group ( all P < 0.05) than that in AP group. However, no significant difference was shown among three remimazolam groups.

Table 4 Secondary outcomes
Full size table

After being injected with the dose of remimazolam for sedation induction, The median time interval for the first addition of remimazolam was 6 min in the AR1 group, 10 min in the AR2 group, and 15 min in the AR3 group. The time interval was significantly extended in the AR2 group (P < 0.0001) and AR3 group (P < 0.0001) compared with the AR1 group (Fig. 3). Moreover, the time interval was also significantly extended in the AR3 group (P < 0.01) compared with the AR2 group (Fig. 3). Alfentanil was added every 15 min after sedation induction for all study groups. There was no statistical difference between the doses of Alfentanil (P = 0.877) and remimazolam (P = 0.201) among AR1-AR3 groups for sedoanalgesia.

Fig. 3
figure 3

The time interval for the first addition of remimazolam. Compared with AR1 group, ****P < 0.0001, compared with AR2 group, ##P < 0.01. The time interval was presented as median (25th–75th centiles). Abbreviations: AR1 alfentanil and remimazolam (0.1 mg/kg); AR2 alfentanil and remimazolam (0.15 mg/kg); AR3 alfentanil and remimazolam (0.2 mg/kg)

Full size image

Though patients in AR2 and AR3 group had lower body movement rate than AR1 group, there was no significant difference among all groups (P = 0.052). Cough (P = 0.482) and bradycardia (P = 0.061) also differed insignificantly among all groups. The incidence of hypotension was significantly decreased for each dose of remimazolam (all P < 0.05), respectively, compared with propofol. Similarly, there was no significant difference among the remimazolam groups. None of the patients developed bradycardia or hypertension during surgery in all study groups.

Patients were followed up 24 h after surgery. Pain occurred in four patients and nausea and vomiting occurred in two patients. Appropriate treatment measures were given to alleviate the postoperative adverse reactions in the ward. There was no significant difference among all groups for pain (P = 0.372) and nausea and vomiting (P = 0.375). No patient developed other adverse reactions, including hypotension, hypertension, bradycardia, tachycardia, vertigo and intraoperative awareness.

Outcomes of monitoring data

The MOAA/S scores and vital signs, including HR (P = 0.218), SpO2 (P = 0.327), RR (P = 0.208) and BIS (P = 0.478), were similar for all study groups at T0 (Supplemental Table 1). The average MAP was significantly higher in AR1-AR3 groups (all P < 0.001) than AP group. All doses of remimazolam produce a similar impact on average MAP. (Fig. 4). At T1, compared with the AP group, MOAA/S scores in the AR1 group, AR2 group and AR3 group did not differ significantly. However, the MOAA/S score in the AR1 group was significantly higher compared with AR2 (P < 0.05) and AR3 (P < 0.05) (Fig. 5), which indicated that patients in the AR2 group and AR3 group had more profound sedation at T1 than those in AR1 group. At T2 and T3, there was no significant difference in MOAA/S scores among all the groups (Fig. 5). BIS values were significantly higher in AR1-AR3 group than AP group (all P < 0.05) at T1, T2 and T3 (Table 5, Fig. 5). Nevertheless, there was no statistical difference in BIS values among the remimazolam doses (Table 5, Fig. 5).

Fig. 4
figure 4

Average MAP. Compared with AP group, ***P < 0.001. The average MAP was presented as mean ± SD. Abbreviations: AP alfentanil and propofol; AR1 alfentanil and remimazolam (0.1 mg/kg); AR2 alfentanil and remimazolam (0.15 mg/kg); AR3 alfentanil and remimazolam (0.2 mg/kg) 

Full size image
Fig. 5
figure 5

MOAA/S and BIS. Compared with AP group, ***P < 0.001, compared with AR1 group, & P < 0.05, compared with AR3 group, # P < 0.05. MOAA/S was presented as median (25th–75th centiles) and BIS was presented as mean ± SD. Abbreviations: AP alfentanil and propofol; AR1 alfentanil and remimazolam (0.1 mg/kg); AR2 alfentanil and remimazolam (0.15 mg/kg); AR3 alfentanil and remimazolam (0.2 mg/kg)

Full size image
Table 5 BIS values at T0, T1, T2, T3 and T4
Full size table

At T4, more than 50% of patients' MOAA/S scores reached at least 4 in AP, AR1 and AR2 groups and 31.0% in AR3 group. Nevertheless, there were no significant differences among all study groups (Fig. 5). BIS values were statistically lower in the AR3 group than AR1 group (P < 0.05, Table 5, Fig. 5). However, compared with the AP group, there was no significant difference in AR1-AR3 groups (Table 5, Fig. 5).

Discussion

When performing colonoscopy, sedatives and analgesics provide patients comfort, improve examination quality and reduce procedure time [29]. In our study, remimazolam or propofol combined with alfentanil had a 100% successful sedation rate for colonoscopic polypectomy. Moreover, patients who received remimazolam combined with alfentanil had better outcomes.

Propofol is widely used for gastrointestinal endoscopy patients, but it has significant limitations, including individual differences in pharmacokinetics and pharmacodynamics, respiratory depression, hypotension, and lack effective antagonists [30]. Remimazolam is similar to midazolam in pharmacodynamics [31]. A carboxylic ester linkage is introduced into its chemical structure, which acts similarly to remifentanil and can be metabolized by nonspecific tissue esterases in blood. A study indicated that remimazolam achieved a moderate depth and duration of sedation by titration and could maintain the stability of vital signs even in deep sedation [32] and was quickly reversed by flumazenil (median time to alert entirely was 1.0 min) [33]. In our research, we observed that patients in remimazolam groups took less time to be fully alert than propofol group. The time to full alert in remimazolam groups was in the range of 3–10 min, which was similar to the findings in previous studies [20, 28]. Patients also reached the standard of leaving PACU more quickly in remimazolam groups than propofol group. However, Chen et al. found no significant difference in the time to full alert between remimazolam and propofol in their phase III clinical trial [21]. Except for the differences in clinical practice (colonoscopy vs. colonoscopic polypectomy), The use of anesthetics also varies (fentanyl-remimazolam vs. alfentanil-remimazolam). These aspects all had impacts on the time to full alert. Also, Tian et al. indicated that elderly patients who received 0.2 mg/kg remimazolam took significantly longer to recover than propofol in upper gastrointestinal endoscopy [34]. Besides the age of patients, differences in the administration of remimazolam and the dosage of propofol may lead to the opposite result.

Intraoperative hypotension is associated with organ injury and poor outcomes [35]. An exploratory analysis suggested more episodes of hypotension when propofol was used for sedation than remimazolam [36]. Furthermore, a series of studies have shown that remimazolam had more stable hemodynamics and a lower incidence of hypotension in multiple surgical types [34, 37,38,39,40,41]. In our study, the incidence of hypotension was lower and a higher average MAP existed in AR groups than AP group. As for the average MAP and the incidence of hypotension among the AR1, AR2 and AR3 groups, no difference was found.

According to the package insert of remimazolam in our study recommends that administer an initial dose intravenously as a 7 mg push injection over a 1-min time period. If necessary, administer supplemental doses of 2.5 mg intravenously over a 15-s time period. We used the mode of single administration in three doses of remimazolam groups. The metabolism of remimazolam was dose-independent and followed the first-order kinetic model [42]. We found that patients received the first additional dose at inconsistent intervals after sedation induction. Patients in the AR2 and AR3 groups took more extended intervals. However, the subsequent addition of remimazolam was performed at an interval of 5–8 min for all remimazolam groups, which was consistent with the context-sensitive half time of remimazolam [43]. Besides, the duration of surgery among the groups did not differ significantly. Therefore, there was no difference in the total doses of remimazolam among the AR1-AR3 groups.

It was highlighted that there were some statistically different results among the AR1, AR2 and AR3 groups. First, the MOAA/S score in the AR1 group was higher than AR2 and AR3 groups at T1, indicating that 0.15 mg/kg and 0.2 mg/kg remimazolam could achieve better sedation at the beginning of the operation. It was necessary for colonoscopic polypectomy because colonoscope insertion, especially in the sigmoid colon, was time-consuming and technically challenging [44], so patients in the initial stage were insulted more severely. Second, BIS values in AR1 group were significantly higher than AR3 group at T4, and the time to full alert was a little longer in AR3 group compared with the AR1 and AR2 groups. Based on the analysis above, although there was no significant difference in the total doses of remimazolam and alfentanil, and the rate of side effects was also similar among the AR1-AR3 groups, remimazolam 0.15 mg/kg might be the first choice for sedation induction because of the suitable depth of sedation at the beginning of the operation and the advantage of a faster recovery in relatively shorter surgery. This result needs to be confirmed by a large sample study further.

BIS monitoring was used to assess the appropriate sedation levels of anesthesia. We found that BIS values (58–69) were significantly higher in AR1-AR3 groups compared with AP group (45–63), which was consistent with previous studies [45,46,47,48]. None of the patients reported intraoperative awareness during surgery for all study groups. We also observed that BIS values were above 60 in some patients even though they received 0.2 mg/kg remimazolam for sedation induction. The BIS values among AR1, AR2 and AR3 groups showed no statistical difference. Therefore, appropriate ranges of the BIS for remimazolam sedation still need more research [47].

In our study, it should also be noted that although remimazolam and propofol can produce enough sedation for colonoscopic polypectomy, propofol is more expensive than remimazolam. In our institution, the cost of a 25 mg vial of remimazolam besylate is 69.8¥, and a 500 mg vial of propofol is 178.3¥. Patients in AR groups needed at most two vials of remimazolam in our research. Based on the suitable sedation and the lower cost, we prefer remimazolam combined with alfentanil sedation for colonoscopic polypectomy.

This study has the following limitations: First, it was a single-center study and the sample size is limited. Hence, our findings did not possess universality. Second, remimazolam should be given additional doses several times due to the 2020 edition package insert in this study. So continuous transfusion of remimazolam could be considered for subsequent studies with the update of the instructions. Third, we only conducted a 24-h postoperative follow-up to evaluate postoperative adverse reactions. Long-term complications were not assessed. Further studies are needed to validate the present findings.

Conclusion

In conclusion, remimazolam combined with alfentanil was a safe alternative for sedation and analgesia during the colonoscopic polypectomy. In particular, there was a low incidence of hypotension and fast full alert. As a novel intravenous benzodiazepine, the safety and feasibility of the anesthesia scheme of remimazolam should be further evaluated.

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Abbreviations

ANOVA:

Analysis of variance

AP:

Alfentanil (10 μg/kg) and propofol (2 mg/kg)

AR1:

Alfentanil (10 μg/kg) followed by remimazolam (0.1 mg/kg)

AR2:

Alfentanil (10 μg/kg) followed by remimazolam (0.15 mg/kg)

AR3:

Alfentanil (10 μg/kg) followed by remimazolam (0.2 mg/kg)

ASA:

American Society of Anesthesiologists

BIS:

Bispectral index; BMI: body mass index

BP:

Blood pressure

CONSORT:

Consolidated Standards of Reporting Trials

CRF:

Case report form

GABAA :

γ-Aminobutyric acid subtype A

HR:

Heart rate

IV:

Intravenous

MAC:

Monitored anesthesia care

MAP:

Mean arterial pressure

MOAA/S:

Modified Observers Assessment of Alertness and Sedation

NA:

Not applicable

PACU:

Post anesthesia care unit

PASS:

Power Analysis and Sample Size

RR:

Respiratory rate

SD:

Standard deviation

SPSS:

Statistical Package for Social Sciences

SpO2 :

Oxygen saturation

References

  1. Chan MT, Wu WK, Tang RS. Optimizing depth of sedation for colonoscopy. Can J Anaesth. 2015;62(11):1143–8.

    Article  PubMed  Google Scholar 

  2. Wu J, Hu B. The role of carbon dioxide insufflation in colonoscopy: a systematic review and meta-analysis. Endoscopy. 2012;44(2):128–36.

    Article  CAS  PubMed  Google Scholar 

  3. Kaminski MF, Robertson DJ, Senore C, Rex DK. Optimizing the Quality of Colorectal Cancer Screening Worldwide. Gastroenterology. 2020;158(2):404–17.

    Article  PubMed  Google Scholar 

  4. Sagiroglu G, Baysal A. Continuous intravenous versus intermittent bolus midazolam with remifentanil during arteriovenous fistula placement with monitored anesthesia care in chronic renal failure patients: a randomized controlled trial. Ann Saudi Med. 2020;40(3):175–82.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Sagiroglu G, Baysal A, Yanik F. The Comparison of two different techniques of remifentanil administration during implantable vascular access device procedures. J Perianesth Nurs. 2021;36(6):664–71.

    Article  PubMed  Google Scholar 

  6. Tetzlaff JE. Practical considerations in the management of sedation for colonoscopy. Curr Opin Anaesthesiol. 2016;29(4):512–8.

    Article  PubMed  Google Scholar 

  7. Goudra B, Gouda G, Mohinder P. Recent Developments in Drugs for GI Endoscopy Sedation. Dig Dis Sci. 2020;65(10):2781–8.

    Article  CAS  PubMed  Google Scholar 

  8. Cote GA, Hovis RM, Ansstas MA, Waldbaum L, Azar RR, Early DS, Edmundowicz SA, Mullady DK, Jonnalagadda SS. Incidence of sedation-related complications with propofol use during advanced endoscopic procedures. Clin Gastroenterol Hepatol. 2010;8(2):137–42.

    Article  PubMed  Google Scholar 

  9. Li M, Ke W, Zhuang S. Effect of intravenous lidocaine on propofol consumption in elderly patients undergoing colonoscopy: a double-blinded, randomized, controlled trial. BMC Anesthesiol. 2022;22(1):61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Baker MT, Naguib M. Propofol: the challenges of formulation. Anesthesiology. 2005;103(4):860–76.

    Article  CAS  PubMed  Google Scholar 

  11. Cho HB, Kwak HJ, Park SY, Kim JY. Comparison of the incidence and severity of cough after alfentanil and remifentanil injection. Acta Anaesthesiol Scand. 2010;54(6):717–20.

    Article  CAS  PubMed  Google Scholar 

  12. Liu SY, Poon CM, Leung TL, Wong CW, Chan YL, Leung TC, Leong HT. Nurse-administered propofol-alfentanil sedation using a patient-controlled analgesia pump compared with opioid-benzodiazepine sedation for outpatient colonoscopy. Endoscopy. 2009;41(6):522–8.

    Article  CAS  PubMed  Google Scholar 

  13. Usta B, Turkay C, Muslu B, Gozdemir M, Kasapoglu B, Sert H, Demircioglu RI, Karabayirli S. Patient-controlled analgesia and sedation with alfentanyl versus fentanyl for colonoscopy: a randomized double blind study. J Clin Gastroenterol. 2011;45(7):e72-75.

    Article  CAS  PubMed  Google Scholar 

  14. Wilhelm W, Kreuer S. The place for short-acting opioids: special emphasis on remifentanil. Critical Care. 2008;12(Suppl 3):S5.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Masui K, Stohr T, Pesic M, Tonai T. A population pharmacokinetic model of remimazolam for general anesthesia and consideration of remimazolam dose in clinical practice. J Anesth. 2022;36(4):493–505.

    Article  PubMed  Google Scholar 

  16. Sigel E, Ernst M. The Benzodiazepine Binding Sites of GABAA Receptors. Trends Pharmacol Sci. 2018;39(7):659–71.

    Article  CAS  PubMed  Google Scholar 

  17. Sneyd JR. Remimazolam: new beginnings or just a me-too? Anesth Analg. 2012;115(2):217–9.

    Article  CAS  PubMed  Google Scholar 

  18. Sneyd JR, Rigby-Jones AE. Remimazolam for anaesthesia or sedation. Curr Opin Anaesthesiol. 2020;33(4):506–11.

    Article  PubMed  Google Scholar 

  19. Wesolowski AM, Zaccagnino MP, Malapero RJ, Kaye AD, Urman RD. Remimazolam: pharmacologic considerations and clinical role in anesthesiology. Pharmacotherapy. 2016;36(9):1021–7.

    Article  PubMed  Google Scholar 

  20. Chen S, Wang J, Xu X, Huang Y, Xue S, Wu A, Jin X, Wang Q, Lyu J, Wang S, et al. The efficacy and safety of remimazolam tosylate versus propofol in patients undergoing colonoscopy: a multicentered, randomized, positive-controlled, phase III clinical trial. Am J Transl Res. 2020;12(8):4594–603.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Chen SH, Yuan TM, Zhang J, Bai H, Tian M, Pan CX, Bao HG, Jin XJ, Ji FH, Zhong TD, et al. Remimazolam tosilate in upper gastrointestinal endoscopy: A multicenter, randomized, non-inferiority, phase III trial. J Gastroenterol Hepatol. 2021;36(2):474–81.

    Article  CAS  PubMed  Google Scholar 

  22. Cao Y, Yang J, Li J, Ao X, Zhang KY, Shen XC, Chen DF, Lan CH. Comparison of procedural sequences in same-day painless bidirectional endoscopy: Single-center, prospective, randomized study. Dig Endosc. 2017;29(3):330–7.

    Article  PubMed  Google Scholar 

  23. Lv S, Sun D, Li J, Yang L, Sun Z, Feng Y. Anesthetic effect of different doses of butorphanol in patients undergoing gastroscopy and colonoscopy. BMC Surg. 2021;21(1):266.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Teng Y, Ou M, Wang X, Zhang W, Liu X, Liang Y, Li K, Wang Y, Ouyang W, Weng H, et al. Efficacy and safety of ciprofol for the sedation/anesthesia in patients undergoing colonoscopy: Phase IIa and IIb multi-center clinical trials. Eur J Pharm Sci. 2021;164:105904.

    Article  CAS  PubMed  Google Scholar 

  25. Xu BB, Zhao XL, Xu GP. Clinical study of anesthetization by dezocine combined with propofol for indolent colonoscopy. World J Gastroenterol. 2016;22(24):5609–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Sato M, Horiuchi A, Tamaki M, Ichise Y, Kajiyama M, Yamamoto Y, Tanaka N. Safety and effectiveness of nurse-administered propofol sedation in outpatients undergoing gastrointestinal endoscopy. Clin Gastroenterol Hepatol. 2019;17(6):1098-1104e1091.

    Article  PubMed  Google Scholar 

  27. Treurniet KM, Berkhemer OA, Immink RV, Lingsma HF, Ward-van der Stam VMC, Hollmann MW, Vuyk J, van Zwam WH, van der Lugt A, van Oostenbrugge RJ, et al. A decrease in blood pressure is associated with unfavorable outcome in patients undergoing thrombectomy under general anesthesia. J Neurointerv Surg. 2018;10(2):107–11.

    Article  PubMed  Google Scholar 

  28. Liu X, Ding B, Shi F, Zhang Y, Liu L, Sha Y, Zhao T. The Efficacy and Safety of Remimazolam Tosilate versus Etomidate-Propofol in Elderly Outpatients Undergoing Colonoscopy: A Prospective, Randomized, Single-Blind, Non-Inferiority Trial. Drug Des Devel Ther. 2021;15:4675–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Childers RE, Williams JL, Sonnenberg A. Practice patterns of sedation for colonoscopy. Gastrointest Endosc. 2015;82(3):503–11.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Goudra BG, Singh PM. SEDASYS, sedation, and the unknown. J Clin Anesth. 2014;26(4):334–6.

    Article  PubMed  Google Scholar 

  31. Saari TI, Uusi-Oukari M, Ahonen J, Olkkola KT. Enhancement of GABAergic activity: neuropharmacological effects of benzodiazepines and therapeutic use in anesthesiology. Pharmacol Rev. 2011;63(1):243–67.

    Article  CAS  PubMed  Google Scholar 

  32. Pastis NJ, Yarmus LB, Schippers F, Ostroff R, Chen A, Akulian J, Wahidi M, Shojaee S, Tanner NT, Callahan SP, et al. Safety and Efficacy of Remimazolam Compared With Placebo and Midazolam for Moderate Sedation During Bronchoscopy. Chest. 2019;155(1):137–46.

    Article  PubMed  Google Scholar 

  33. Worthington MT, Antonik LJ, Goldwater DR, Lees JP, Wilhelm-Ogunbiyi K, Borkett KM, Mitchell MC. A phase Ib, dose-finding study of multiple doses of remimazolam (CNS 7056) in volunteers undergoing colonoscopy. Anesth Analg. 2013;117(5):1093–100.

    Article  CAS  PubMed  Google Scholar 

  34. Tan Y, Ouyang W, Tang Y, Fang N, Fang C, Quan C. Effect of remimazolam tosilate on early cognitive function in elderly patients undergoing upper gastrointestinal endoscopy. J Gastroenterol Hepatol. 2022;37(3):576–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Gregory A, Stapelfeldt WH, Khanna AK, Smischney NJ, Boero IJ, Chen Q, Stevens M, Shaw AD. Intraoperative Hypotension Is Associated With Adverse Clinical Outcomes After Noncardiac Surgery. Anesth Analg. 2021;132(6):1654–65.

    Article  CAS  PubMed  Google Scholar 

  36. Sneyd JR, Absalom AR, Barends CRM, Jones JB. Hypotension during propofol sedation for colonoscopy: an exploratory analysis. Br J Anaesth. 2021;128(4):610–22.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Mao Y, Guo J, Yuan J, Zhao E, Yang J. Quality of Recovery After General Anesthesia with Remimazolam in Patients’ Undergoing Urologic Surgery: A Randomized Controlled Trial Comparing Remimazolam with Propofol. Drug Des Devel Ther. 2022;16:1199–209.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Shi F, Chen Y, Li H, Zhang Y, Zhao T. Efficacy and Safety of Remimazolam Tosilate versus Propofol for General Anesthesia in Cirrhotic Patients Undergoing Endoscopic Variceal Ligation. Int J Gen Med. 2022;15:583–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Xiao X, Xiao N, Zeng F, Chen H, Zhang L, He X. Gastroscopy sedation: clinical trial comparing propofol and sufentanil with or without remimazolam. Minerva Anestesiol. 2022;88(4):223–9.

    Article  PubMed  Google Scholar 

  40. Zhang J, Wang X, Zhang Q, Wang Z, Zhu S. Application effects of remimazolam and propofol on elderly patients undergoing hip replacement. BMC Anesthesiol. 2022;22(1):118.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Zhang X, Li S, Liu J. Efficacy and safety of remimazolam besylate versus propofol during hysteroscopy: single-centre randomized controlled trial. BMC Anesthesiol. 2021;21(1):156.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Antonik LJ, Goldwater DR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg. 2012;115(2):274–83.

    Article  CAS  PubMed  Google Scholar 

  43. Morimoto Y. Efficacy and Safety Profile of Remimazolam for Sedation in Adults Undergoing Short Surgical Procedures. Ther Clin Risk Manag. 2022;18:95–100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Kravochuck S, Gao R, Church J. Differences in colonoscopy technique impact quality. Surg Endosc. 2014;28(5):1588–93.

    Article  CAS  PubMed  Google Scholar 

  45. Doi M, Hirata N, Suzuki T, Morisaki H, Morimatsu H, Sakamoto A. Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class III): results of a multicenter, randomized, double-blind, parallel-group comparative trial. J Anesth. 2020;34(4):491–501.

    Article  PubMed  Google Scholar 

  46. Doi M, Morita K, Takeda J, Sakamoto A, Yamakage M, Suzuki T. Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth. 2020;34(4):543–53.

    Article  PubMed  Google Scholar 

  47. Liu T, Lai T, Chen J, Lu Y, He F, Chen Y, Xie Y. Effect of remimazolam induction on hemodynamics in patients undergoing valve replacement surgery: a randomized, double-blind, controlled trial. Pharmacol Res Perspect. 2021;9(5):e00851.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Shirozu K, Nobukuni K, Tsumura S, Imura K, Nakashima K, Takamori S, et al. Neurological sedative indicators during general anesthesia with remimazolam. J Anesth. 2022;36(2):194–200.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, China

    Yueyang Xin, Tiantian Chu, Jinxu Wang & Aijun Xu

Authors
  1. Yueyang Xin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tiantian Chu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jinxu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aijun Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization and project administration: AJX, Data curation: YYX, TTC and JXW, Formal analysis and methodology: AJX, YYX, TTC and JXW, Writing—original draft and writing—review & editing: AJX and YYX. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Aijun Xu.

Ethics declarations

Ethics approval and consent to participate

Ethics approval was received from Tongji Medical College of Huazhong University of Science and Technology. Approved No. of Ethics Committee: 2021-S068 and registered at http://www.chictr.org.cn (16/05/2021, ChiCTR2100046492). The study protocol followed the CONSORT guidelines. The study protocol was performed following the Declaration of Helsinki. Written informed consent to participate in this study was obtained from participants.

Consent for publication

Not application.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1. Supplemental Table 1.

Vital signs at T0, T1, T2, T3 and T4; Data are presented as mean ± SD and median (25th–75th centiles). We summarized and analyzed vital signs of patients at T0, T1, T2, T3 and T4.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xin, Y., Chu, T., Wang, J. et al. Sedative effect of remimazolam combined with alfentanil in colonoscopic polypectomy: a prospective, randomized, controlled clinical trial. BMC Anesthesiol 22, 262 (2022). https://doi.org/10.1186/s12871-022-01805-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12871-022-01805-3

Keywords

  • Alfentanil
  • Colonoscopic surgical procedure
  • Deep sedation
  • Remimazolam besylate

BMC Anesthesiology

ISSN: 1471-2253

Contact us